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Abstract 
Purpose: To use differential scanning calorimetry (DSC) to predict the liquefaction time and dissolution 
profile of some commercial paracetamol suppositories as well as paracetamol suppositories formulated 
with palm oil base.  
Methods:  The suppository base was prepared by mixing hydrogenated palm oil and palm kernel 
stearin in a ratio of 8:2. Three commercial paracetamol suppositories (A, B, and C) were purchased, 
while product D, paracetamol suppository was formulated with suppository base using the double 
casting method. In-vitro drug release from suppositories was determined using DSC and the effect of 
liquefaction on drug release was studied. The relationship between suppository melting and dissolution 
was analysed statistically.  
Results: The melting temperature of products A and B were 41.0 and 40.0 ºC respectively, whereas 
those of products C and D were 35.9 and 33.1 ºC, respectively. The liquefaction time of the 
suppositories were 61.4 (A), 54.2 (B), 9.0 (C) and 7.4 min (D). Less than 40 % paracetamol was 
released from products A and B in 2 h, while products C and D showed good dissolution with > 95 % 
drug release in 15 min. Statistical analysis using Pearson’s test indicates that the proportion of melt in 
the suppository base correlates well with drug release (p < 0.05).  
Conclusion: Paracetamol release from palm oil suppositories is rapid and correlates with melting of the 
base. DSC can be used to predict drug release in paracetamol suppository formulations. 
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Oral route of drug administration is the preferred 
choice in drug delivery. However, other routes of 
drug administration have proved to be equally 
good in some situations and sometimes is an 
unavoidable choice in drug therapy.  The rectal 
route of drug administration is one such route 
normally opted for in geriatric and paediatric 
patients and in those cases where the oral route 
is not viable, especially in conditions such as 
nausea, vomiting, convulsion, difficulty in 
swallowing, gastric irritation, inactivation of drugs 
in the gastric environment and first-pass effect on 
drugs [1,2]. The rectal route has several 
limitations such as lower surface area, poor 
absorption, poor dissolution due to limited fluid 
content, inactivation by microbes and poor 
patient compliance. Nonetheless, in spite of 
these limitations, the rectal route still can be an 
effective route of administration.  
 
Suppositories designed to deliver drugs to the 
rectum upon insertion will soften or melt at rectal 
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temperature, releasing the active drug to the site 
of absorption. Usually, fatty bases with a melting 
point near rectal temperature are used in 
suppositories as vehicles. Fatty acid base 
suppositories melt and release the embedded 
drug from the suppository matrix into the mucous 
layer of the rectal lining and dissolve in the rectal 
fluid. Drug in the rectal fluid diffuses through the 
epithelium mucous layer of the rectal wall, 
usually by passive diffusion and enters the 
systemic circulation [3]. The rate of absorption 
depends on factors such as the rate at which 
drug release occurs from the suppository, 
concentration at the absorption site, excipient 
properties, solubilisation in the rectal fluids and 
the ability of the drug to cross the membrane 
barrier at the site of absorption [4].  
 
Although there are multiple events during the 
absorption of drug in the rectum, the melting of 
suppository base will determine the release and 
absorption of drug to a significant extent. If the 
suppository does not melt readily to spread over 
the absorbing surface, the bioavailability of the 
embedded drug will be hindered. Hence, the 
melting temperature of a fatty suppository base is 
a limiting factor for drug absorption into the 
systemic circulation. Cocoa butter (theobroma 
oil) is often considered to be the ideal 
suppository base. But due to its polymorphic 
tendency, its use is limited. Palm products having 
melting characters identical to that of theobroma 
oil as well as good stability will be an excellent 
substitute suppository base. 
 
Several in-vitro tests are described in 
pharmaceutical compendia to correlate in-vitro 
and in-vivo performance of dosage forms in order 
to assure the quality, purity and uniformity in the 
formulations. Unfortunately, many tests are 
limited to solid pharmaceutical dosage forms and 
there is no reliable, robust and rapid technique to 
predict the in-vivo performance of suppositories. 
Due to a lot of variability in suppository dosage 
forms, it is difficult to predict in-vivo drug release 
with merely a single test. Although there are 
different methods in the literature, the results 
have been erratic and case specific. Hence, 
there is need to develop a simple, quick, and 
robust method which can be used to predict drug 
release from suppositories. 
 
To assess the quality of a suppository as a drug 
delivery system, quality tests such as liquefaction 
time, softening time, disintegration and 
dissolution have been prescribed in the literature 
[5,6]. In this study, an attempt was made to use 
DSC in determining the liquefaction time and 
dissolution profile of paracetamol suppositories in 
order to characterize the drug release from both 





Paracetamol suppository 125 mg (Product A) 
and paracetamol suppository 250 mg (Product B) 
produced by the same manufacturer were 
purchased from a pharmacy in the Klang Valley, 
Kuala Lumpur, Malaysia.  Paracetamol 
suppository 125 mg (Product C) manufactured by 
a different manufacturer, was purchased from the 
same pharmacy. Paracetamol suppository 125 
mg (Product D) was extemporaneously prepared 
according to the method described below. 
Hydrogenated palm kernel oil (Batch No. 
0040933801), and hydrogenated palm kernel 
stearin (Batch No. 0091420002) were obtained 
from Cargill (M) Sdn Bhd, Kuala Lumpur, 
Malaysia. Stearic acid (Batch No. Tristar 149), 
glyceryl monostearate (Batch No. E01/096) and 
paracetamol (BP grade, Batch No. 020766) were 
donated by Hesego Industry (M) Sdn Bhd, 
Esterchem (M) Sdn. Bhd., and Raza 
Manufacturing Sdn Bhd, Kuala Lumpur, 
Malaysia, respectively. Other chemicals, which 
were of analytical grade, were purchased from 
Sigma-Aldrich Corp, St. Louis, USA and Fisher 
Scientific, Houston, USA. 
 
PREPARATION OF SUPPOSITORY BASE 
 
Palm kernel oil suppository base was prepared 
by mixing hydrogenated palm kernel oil and 
hydrogenated palm kernel stearin (8:2) using 
Erweka mixer (model AR 402) at 45 ºC and 
paddle stirrer speed of 100 rpm, followed by the 
addition of stearic acid (5 % w/w) and glyceryl 
monostearate (5 % w/w), according to our 
previously described method [7]. The blend was 
allowed to solidify at 25 ºC for one week and 
thereafter kept at 4 ºC until use. 
 
PREPARATION OF PARACETAMOL 
SUPPOSITORIES 
 
Paracetamol suppositories with a dosage 
strength of 125 mg each were prepared by 
melting the suppository base and incorporating 
sufficient paracetamol.  In brief, the double 
casting method was adopted, and after the initial 
determination of the displacement value, the 
suppository base was melted at around 40 oC. 
Subsequently, paracetamol was incorporated 
and gentle stirring was applied until a 
homogenous mixture of the base and drug was 
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achieved. The molten mass was poured into 
stainless steel suppository moulds and the 
paracetamol suppositories were allowed to 
solidify at 25 ºC for 60 min before being released 
from the mould. A batch of 60 suppositories 
weighing about 1 g was prepared and used for 
the study immediately.    
 
THERMAL ANALYSIS  
 
The method adopted for the thermal study is 
similar to that reported in our previous work with 
few modifications [7]. Briefly, a differential 
scanning calorimeter (DSC 6, Perkin Elmer, 
USA) was connected to a chiller and a thermal 
analysis gas station (Perkin Elmer) to control the 
flow of the purge gas, nitrogen, at a flow rate of 
20 ml/min.  The DSC pans used were 50 µl 
closed aluminium pans with perforation. Indium 
and zinc (Perkin Elmer) were used to calibrate 
the DSC. Each sample weighing between 2.5 - 
4.0 mg (UMT2 Microbalance, Mettler Toledo, 
Inc., USA) was scanned from 3.5 to 70 ºC at 5 
K/min.  
 
Determination of liquefaction time 
 
Liquefaction test is usually done on suppositories 
to learn about the behaviour of suppositories in 
the rectal environment. The test is commonly 
referred to as Krowczynski’s method and it 
measures the time needed for a suppository to 
liquefy in-vitro under conditions akin to the 
rectum [8]. The liquefaction time of the 
suppositories was determined by a custom made 
apparatus according to the specifications stated 
in the British Pharmacopoeia, 2000 [9].   The 
apparatus consists of three glass tubes 
immersed in water bath maintained at 37 C. 
One end of the tube was closed and the other 
end was open for holding a glass rod. During the 
study 5 ml of distilled water maintained at 37 C 
was poured into each of the tubes. Suppositories 
were inserted into the tubes with the tip facing 
downwards. Glass rod was placed above the 
suppositories, liquefaction time was recorded 
from the moment glass rod was placed on the 
suppository to the moment it just touches the tip 
of the glass tube.   
 
In-vitro dissolution study 
 
USP rotating basket method [10] was adopted for 
the dissolution study using Erweka dissolution 
apparatus (DT 70, Erweka GmbH, Germany). 
Five suppository samples were tested for each 
preparation. Each suppository was placed in the 
basket, lowered into the dissolution vessel 
containing 900 ml of dissolution medium at 37 C 
and the basket rotated at 100 rpm. Samples (2 
ml) were withdrawn from the dissolution medium, 
filtered through 0. 22 µm filter and their 
absorbance measured at 244 nm using a 
spectrophotometer (1240 Mini UV, Shimadzu, 
Japan). The content of paracetamol was then 
determined from the absorbance using a 
standard curve for paracetamol at concentrations 
ranging from 15 to 300 µg/ml. The accuracy of 
this method was assessed by spiking three 
known amounts of paracetamol (75, 150 and 250 
µg/ml; n = 5 for each concentration) into the 




Statistical significance was performed using 
Prism 3 software (GraphPad Software, Inc., 
USA). The data were expressed as mean ± 
standard deviation (SD, n = 5), and analysed by 
Pearson’s correlation test. Statistically significant 




Drug release from a suppository usually starts 
after melting of the suppository in the rectum and 
this is influenced by temperature, as well as the 
lipophilic and hydrophilic properties of the base, 
rectal fluids, surfactants and drug concentration 




The results in Table 1 show that the melting point 
of suppository A and B is 41.0 and 40.0 C, 
respectively, and are higher than the body 
temperature (37 °C). Thus, products A and B 
required prolonged time and elevated 
temperature to achieve complete melting. 
Products C and D showed melting points of 35.9 
and 33.1°C, respectively, which were less than 
body temperature, and also exhibted short 




The melt profiles of the suppositories, heat flow 
into the suppositories and subsequent phase 
transitions are depicted in the DSC thermograms 
shown in Fig 1. 
 
The comparison of melting (%) and drug release from 
the suppositories in 15 min is shown in Figure 2. 
 
In-vitro drug release studies 
 
Drug release from products A and B in 15 min 
was 1.2 and 6.4 %, respectively, while for C and 
D, it was 95.6 and 99 % (Table 2). 
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Table 1:  Melting characteristics of suppositories (mean  SD, n = 5) 
 




e at 100 % 
melt (°C) 
Time interval 
between 0 and 
100 % melt (min) 
Starting and end 
melting points 
(min) 
A 61.4±1.7 41.02.8 63.410.8 22.50.2 12-22.5 
B 54.2±1.7 40.00.6 46.11.7 18.50.3 3-18.5 
C 9.0±0.5 35.91.7 38.11.4 7.10.5 1-7.1 
D 7.4±0.4 33.11.4 36.81.6 7.00.2 2-7 










Among several factors, the melting 
characteristics of any suppository will determine 
its bioavailability and therapeutic efficacy to a 
significant level [12]. However, there are 
suppositories in which drug release occurs by 
slow dissolution instead of melting.  
 
Modern thermal analysis has advanced in the 
last few decades and has a useful tool in drug 
development. Differential scanning calorimetry 
(DSC) is a powerful thermal analytical technique 
that has been extensively employed in the core 
areas of pharmaceutical development. It is 
usually used to determine drug purity, stability, 
content, melting point assessment, 
polymorphism, and compatibility between drug 
and excipients [11]. DSC measures the heat flow 
into or out of the sample and subsequent phase 
transitions under controlled environment over a 
wide range of temperature conditions 
programmed at a predetermined rate.  
 
The thermograms of all the four suppositories 
have noticeable differences indicating the 
complexity of the composition of the suppository 
bases used by different manufacturer.  Product A 
showed a broad thermogram, attributed to 
complex fatty acids in the base with different 
thermal characters. In product A melting started 
at 12 min and ended at 22.5 min and had a peak 
melting temperature of 41 °C. Similarly product B 
showed 40 °C as peak melting temperature with  
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Fig. 2:  Plots of paracetamol release  (▲)  and proportion of melt (■) versus time for 
suppositories A, B, C and D, respectively   
 
        Table 2: Drug release from the suppositories (mean ± SD, n = 5) 
 






C Suppository D 
0 0 0 0 0 
5.0 0.2±0.0 0.1±0.0 19.2±0.8 22.7±2.4 
10.0 0.3±0.0 0.7±0.1 65.2±1.2 83.2±3.7 
15.0 1.2±0.2 6.4±0.6 95.6±0.9 99.0±0.8 
30.0 1.7±0.1 12.7±0.9 97.1±0.8 99.9±0.5 
60.0 6.6±1.3 32.1±2.1 97.4±1.0 100.2±0.5 
90.0 10.8±0.8 34.9±0.4 98.2±1.2 100.8±1.5 
120.0 14.6±1.0 35.3±0.7 98.6±2.0 100.6±1.7  
Statistical analysis revealed significant correlation between drug release and degree of 
suppository melt for all four formulations, with correlation coefficient (r2) values ranging from 
0.7620 to 0.9877 and p values of 0.0001 to 0.0280. Furthermore, liquefaction time and the 
time taken to achieve complete melting were also correlated (Pearson’s test, r2 = 0.9946 and 
p = 0.0054). 
 
3 min as starting and 18.5 min as the end point. 
 
Both these products were from the same 
manufacturer and probably might have used 
similar base. The thermogram of the product B is 
sharper with narrow thermal range for the base. 
Due to batch to batch variation, dose difference 
(product A and B), possible polymorphic forms, 
variable constituents of base or stability of base, 
the thermograms differ with each other. Usage of 
suppository bases like PEGs in product A and B 
which release the drug by dissolution rather than 
melting cannot be overruled.  
 
In product C melting started at 1 min and ended 
at 7.1 min. The peak melting temperature was 
35.9 °C. The thermogram of the product C 
resembles that of theobroma oil showing close 
polymorphic peaks. Theobroma oil has several 
polymorphic forms of which three forms are 
stable with different melting temperatures, 17, 22 
and 33 °C. These polymorphic forms precipitate 
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in the theobroma base upon overheating the 
base during suppository preparation. Probably 
due to the presence of these polymorphic forms 
the thermogram of product C has shown 
polymorphic peaks. Product D started melting at 
2 min and ended at 7 min. Its thermogram was 
relatively sharper with peak melting temperature 
of 33.1 °C. Palm oil base has selective fatty 
acids as it was the composition of hydrogenated 
palm kernel oil and palm kernel stearin at 8:2 
ratios, these selected pure components exhibited 
rapid, sharp melting characters in product D. 
Temperature required to melt 100 % of the base 
also has considerable variation among the 
products with 63.4, 46.1, 38.1 and 36.8 °C for A, 
B, C, D respectively. 
 
Phase transitions depend, to a large extent, on 
the physicochemical properties of the ingredients 
in the suppository, and can influence liquefaction 
time and dissolution. Products A and B showed 
high liquefaction time of 61.4 and 54.2 min, 
respectively. On the other hand, the liquefaction 
time of products C and D was 9.0 and 7.4, 
respectively. As per the pharmacopoeial 
requirement liquefaction time should be less than 
30 min. These results suggest that products C 
and D will melt rapidly after insertion into the 
rectum.  
 
Products A and B failed to achieve complete 
drug release after 2 h while products C and D 
released > 95 % of after the drug in 15 min. 
Excipients can inhibit drug release from 
suppository matrice. The mechanism of drug 
release from the above suppositories might be 
influenced by the viscosity of the molten 
suppositories. The poor drug release from 
products A and B can be attributed to their un-
melted or partially melted base. Whereas 
products C and D has higher drug release with 
complete or near complete melt.  Thus in the 
present study molten base might have regulated 
the drug release due to changes in the viscosity   
[12,13]. The suppositories prepared with palm oil 
base (D) offered good melting and drug release 
properties and thus, palm oil base may be a 
good replacement for cocoa butter. 
 
The results obtained showed a correlation 
between thermal analysis and in vitro drug 
release, and this is significant from quality control 
perspective of suppository dosage forms. United 
States Food and Drug Administration (USFDA) in 
their guidelines in 2003 [14] stresses the 
importance of in-vitro/in-vivo correlations for 
pharmaceutical dosage forms. The present study 
will suggests that DSC is a suitable alternative to 
conventional dissolution tests for the evaluation 
of in-vitro drug release from suppositories. Thus, 
unlike other pharmaceutical dosage forms, it may 
be possible to obtain a good correlation between 
in-vitro and in-vivo performance of suppositories 
using the tool of thermal analysis, [15,16]. A 
major advantage of DSC is that it is relatively 
simple, robust and rapid.   
   
CONCLUSION 
 
DSC would be particularly suitable for the 
evaluation of suppository formulations to predict 
dissolution rate in a short period. Although it 
cannot be used as a replacement for existing in-
vitro dissolution studies, the method can serve as 
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